News
Data from three terminally ill cardiogenic shock patients showcase potential of procizumab to safely reverse shock within 48 hours and p ...
1d
MedPage Today on MSNFinerenone Gets Expanded FDA Approval in Heart FailureThe FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.
Berlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for finerenone (Kerendia), a ...
7d
Health on MSNDoes Coconut Water Really Make You Poop?Coconut water is hydrating and contains nutrients that can benefit regularity. However, it should be consumed in moderation ...
Women diagnosed with premenstrual symptoms have a slightly increased risk of developing cardiovascular disease later in life.
Researchers found an 11% higher risk for cardiovascular disease in women diagnosed with severe symptoms, not just mild or ...
3d
News-Medical.Net on MSNPremenstrual symptoms linked to higher risk of cardiovascular diseaseWomen diagnosed with premenstrual symptoms have a slightly increased risk of developing cardiovascular disease later in life.
Women diagnosed with premenstrual symptoms have a slightly increased risk of developing cardiovascular disease later in life.
ARO-C3 is an investigational RNA interference therapeutic designed to reduce liver production of complement component 3 as a potential therapy for various complement-mediated diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results